Helping you gain understanding of statistical data to protect your investment

BioRankings LLC provides statistical support to investors, academic and corporate researchers. We have significant experience analyzing basic, preclinical, and clinical data in a wide range of medical and biotechnology areas. We offer a range of services including independent statistical analysis of industry-sponsored papers, due diligence for the pharmaceutical investor, and statistical consulting for the biotechnology industry.

Please browse our full list of services and feel free to contact us anytime.

Bill Shannon, PhD

BioRankings, LLC

Founder and President

314-704-8725

 

Associate Professor of Biostatistics in Medicine

Washington University School of Medicine

 

To contact us:

 

Elena Deych and Bill Shannon’s paper from the 2009 IFCS conference:

Microarray Dimension Reduction Based on Maximizing Mantel Correlation Coefficients Using a Genetic Algorithm Search Strategy

 

Also download the presentation slides:

Probe Selection from Microarray Data

 

We present the GA-Mantel algorithm to find in high dimensional microarray data a subset of genes that captures relevant spatial relationships among the samples, in order to reduce the data for further analysis and eventually to identify meaningful biological markers. GA-Mantel uses a genetic algorithm to search over possible probe subsets using the Mantel correlation as the scoring measure for assessing the quality of any given probe subset, and consensus methods for selecting the final list of important genes. GA-Mantel is evaluated on both artificial data sets and on experimental microarray data taken from leukemia patients. Current results indicate the GA-Mantel method exhibits promise as a way of efficiently identifying information-rich gene subsets in large data sets while avoiding the curse of dimensionality.

 

 

 

Statistical Due Diligence in Biotechnology: Investing in biotechnology is a risk, but performing statistical due diligence on clinical data can expose hidden strengths and weaknesses that make your investment less of a gamble.

 

The field of statistical due diligence has not been officially established like other practices in the due diligence process, but we believe that performing statistical due diligence should be routine for the biotechnology and pharmaceutical investor.

 

We have posted a brief technical report here and on our LinkedIn web page that begins the discussion of what 'statistical due diligence' is, and what it means for the investor and biotech industry.  Over the next several weeks we will  post other reports expanding on this concept.

Tech Sheets

Statistical Power and Sample Size: We recently sent a memo to a small biotech device company CEO and VP for research that explained our reasoning behind the proposed sample size for a study they decided to fund. They responded that the memo's clarity allowed them for the first time to really understand power and sample size calculations. You can download the memo by clicking the link above, or visit the original on LinkedIn.